Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
Open Access
- 15 November 2007
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 110 (10) , 3561-3563
- https://doi.org/10.1182/blood-2007-07-099481
Abstract
Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago. Seventeen (21%) patients died within the first year of treatment, of treatment-related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared with 50 months for those not achieving a CR (P < .001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR.Keywords
This publication has 18 references indexed in Scilit:
- Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosisBlood, 2007
- Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosisBone Marrow Transplantation, 2007
- Transplantation for amyloidosisCurrent Opinion in Oncology, 2007
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisBlood, 2006
- Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trialBlood, 2006
- The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)Blood, 2005
- Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationBlood, 2004
- Molecular Mechanisms of AmyloidosisNew England Journal of Medicine, 2003
- Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosisAmyloid, 2003
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996